- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 2.1 EX-2.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.5 EX-10.5
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 10.50 EX-10.50
- 10.51 EX-10.51
- 10.52 EX-10.52
- 10.53 EX-10.53
- 10.54 EX-10.54
- 10.55 EX-10.55
- 10.56 EX-10.56
- 10.57 EX-10.57
- 10.58 EX-10.58
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.3 EX-99.3
- 99.4 EX-99.4
- EX-FILING FEES Ex-filing Fees
- Download Excel data file
- View Excel data file
- 13 Mar 24 POS EX Additional exhibits for listing
- 13 Mar 24 424B3 Prospectus supplement
- 15 Feb 24 EFFECT Notice of effectiveness
- 14 Feb 24 424B3 Prospectus supplement
- 13 Feb 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 12 Feb 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Jan 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Dec 23 S-4 Registration of securities issued in business combination transactions
- 13 Feb 24 Registration of securities issued in business combination transactions (amended)
- 12 Feb 24 Registration of securities issued in business combination transactions (amended)
- 29 Jan 24 Registration of securities issued in business combination transactions (amended)
- 15 Dec 23 Registration of securities issued in business combination transactions
Exhibit 99.3
Consent of Cowen and Company, LLC
The Board of Directors
Homology Medicines, Inc.
One Patriots Park
Bedford, Massachusetts 01730
The Board of Directors:
We hereby consent to the inclusion of our opinion letter, dated November 15, 2023, to the Board of Directors of Homology Medicines, Inc. (“Homology”), as Annex H to, and reference to such opinion letter under the headings “PROSPECTUS SUMMARY — Opinion of Homology’s Financial Advisor” and “THE MERGER — Opinion of Homology’s Financial Advisor” in, the proxy statement/prospectus relating to the proposed transaction involving Homology and Q32 Bio Inc., which proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of Homology (the “Registration Statement”). By giving such consent, we do not thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term “expert” as used in, or that we come within the category of persons whose consent is required under, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
Very truly yours, |
/s/ Cowen and Company, LLC |
Cowen and Company, LLC |
December 15, 2023